ArticleCureus2026
Triglyceride-Glucose Index as a Predictor of Short-Term Outcomes in Acute Ischemic Stroke: A Prospective Observational Study From Bangladesh.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Acute ischemic stroke (AIS) is a primary cause of death and disability globally, imposing a significant burden in Bangladesh. Preliminary prognostic evaluation continues to be difficult, especially in resource-constrained environments. The triglyceride-glucose (TyG) index, an indicator of insulin resistance (IR), has surfaced as a possible predictor of poor outcomes in stroke. This study aimed to evaluate the association and predictive performance of the TyG index for short-term outcomes among patients with AIS. The primary objective was to assess its association and predictive ability for in-hospital mortality, while the secondary objective was to evaluate its association with 90-day functional outcome. Methods This prospective observational study was carried out in the Department of Neurology, National Institute of Neurosciences and Hospital (NINS), Dhaka, from January 2024 to June 2025. A total of 120 patients with radiologically confirmed first-ever AIS were included, of whom 118 completed the 90-day follow-up. Demographic data, clinical status, comorbidities, admission stroke severity, and laboratory values were gathered. Patients were observed for in-hospital mortality, and 90-day functional outcomes were evaluated using the modified Rankin Scale (mRS). The TyG index was calculated from fasting triglyceride and fasting plasma glucose levels measured within 24 hours of admission. Results The average age of participants was 63.38 ± 14.49 years, with 61.9% (n=73) being male. The in-hospital mortality rate was 28.8% (n=34). A higher TyG index was strongly linked with in-hospital mortality (median 9.49 vs. 8.85, p-value: 0.001). In multivariate logistic regression analysis, the TyG index remained an independent predictor of death (OR: 2.84; 95% CI: 1.43-5.64; p-value: 0.003). The ROC analysis showed moderate predictive performance (AUC: 0.680, p-value: 0.002), with an appropriate cutoff value of ≥8.87 (sensitivity 79.41%, specificity 51.19%). At 90 days, poor functional outcome was observed in 105 (89.0%) patients, which may reflect the tertiary-care hospital setting and inclusion of clinically more severe admitted stroke cases. A higher TyG index was significantly associated with poor functional outcome (OR: 2.21, 95% CI: 1.023-4.798; p=0.044). Patients with a higher TyG index had significantly lower survival rates, according to Kaplan-Meier analysis (log-rank p-value: <0.001). Conclusion A higher TyG index was significantly associated with increased mortality and poor functional outcomes among patients with AIS. However, its discriminative ability was moderate; therefore, the TyG index may be considered only as a simple, low-cost adjunct marker for early risk assessment rather than a standalone prognostic tool, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.